Skip to main content
. 2019 Feb 13;69(8):1278–1287. doi: 10.1093/cid/ciy1105

Table 3.

Univariable and Multiple Cox Regression Analysis of Predictors Associated With Treatment Failure or Death Among Rifampicin-resistant Tuberculosis Patients

Variable N Died or Failed, n (%) Crude HR
(95% CI)
P Value Adjusted HR (95% CI) P Value
Age, years
 <20 13 3 (23.1) 1.00
 20–24 18 6 (33.3) 1.67 (.31–9.14) .552
 25–39 74 18 (24.3) 1.41 (.32–6.17) .647
 40–59 44 9 (20.4) .92 (.18–4.54) .914
 >60+ 10 3 (30.0) 1.54 (.22–10.92) .667
Sex
 Female 50 17 (34.0) 1.00
 Male 109 22 (20.1) .53 (.26–1.11) .091
HIV Status
 Negative 117 25 (21.4) 1.00 1.00
 Positive 16 5 (31.2) 1.191 (.65–5.62) .239 2.83 (.77–10.39) .116
 Unknown 24 9 (37.5) 1.56 (.62–3.92) .340 0.74 (.23–2.40) .622
Sputum smear microscopy for AFB
 Negative 39 11 (28.2) 1.00
 Positive 120 28 (23.3) .87 (.38–1.97) .748
TB category
 New cases 64 18 (28.1) 1.00
 Re-treatment cases 95 21 (22.1) .58 (.28–1.22) .152
TB episode number
 Per 1 prior
episode of TB
159 .67 (.39 - 1.15) .143
Days from result to treatment 141 1.00 (.99–1.00) .687
MDR-TB regimen
 20/24-month 114 24 (21.1) 1.00
 9-month 36 6 (16.7) 1.02 (.41–2.56) .963
DOT
 No 26 13 (50.0) 1.00 1.00
 Yes 124 17 (13.7) .35 (.15–.81) <.001 .29 (.11–.74) .010
SAEs
 None 134 25 (18.7) 1.00
 Any SAE 25 14 (56.0) 5.08 (2.42–10.66) <.001 4.81 (2.04–11.30) <.001

Abbreviations: AFB, acid-fast bacilli; CI, confidence interval; DOT, directly observed therapy; HIV, human immunodeficiency virus; HR, hazard ratio; MDR, multidrug resistant; SAE, serious adverse event; TB, tuberculosis.